Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy

Mike Bogetofte Barnkob, Kristoffer Vitting-Seerup, Lars Rønn Olsen

Research output: Contribution to journalComment/debateResearchpeer-review

3 Downloads (Pure)

Abstract

The development of novel chimeric antigen receptor (CAR) cell therapies is rapidly growing, with 299 new agents being reported and 109 new clinical trials initiated so far this year. One critical lesson from approved CD19-specific CAR therapies is that target isoform switching has been shown to cause tumour relapse, but little is known about the isoforms of CAR targets in solid cancers. Here we assess the protein isoform landscape and identify both the challenges and opportunities protein isoform switching present as CAR therapy is applied to solid cancers.

Original languageEnglish
Article numberltac009
JournalImmunotherapy Advances
Volume2
Issue number1
Number of pages4
DOIs
Publication statusPublished - 20. Apr 2022

Fingerprint

Dive into the research topics of 'Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy'. Together they form a unique fingerprint.

Cite this